Company: DMAC
Filing Date: 2025-08-01
Form Type: S-3
Source: 0001437749-25-024290
Chunk: 47

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-01
Form: S-3
Chunk 47
---
 all fees and expenses incident to our performance of or compliance with the Registration Rights Agreement.

<div align='center'>31</div>

2024 Private Placement

On June 25, 2024, we entered into securities purchase agreements with the selling shareholders pursuant to which we issued and sold to the selling shareholders an aggregate of 4,720,000 newly issued common shares, for aggregate gross proceeds of $11.8 million. The 2024 private placement closed on June 28, 2024, at which time we entered into a registration rights agreements with the selling shareholders. TomEnterprise Private AB (formerly TomEqt Private AB), Trill AB, Dialectic Life Sciences SPV LLC, the Lytton-Kambara Foundation, Drake Private Investments, LLC, Leon Cooperman, who has voting and investment control over the common shares held by The Leon and Toby Cooperman Family Foundation, 21 April Fund, Ltd., Hardy Capital Ltd., Alejandro Moreno, and 21 April Fund, L.P. participated in the 2024 private placement.

2023 Private Placement

On June 21, 2023, we entered into a securities purchase agreement, pursuant to which we issued and sold an aggregate of 11,011,406 newly issued common shares, for aggregate gross proceeds of $37.5 million. The 2023 private placement closed on June 23, 2023, at which time we entered into a registration rights agreements with the investors. TomEnterprise Private AB (formerly TomEqt Private AB), Trill AB, the Lytton-Kambara Foundation, Dialectic Life Sciences SPV LLC, Leon Cooperman, who has voting and investment control over the common shares held by The Leon and Toby Cooperman Family Foundation, Reginald Hardy, who has voting and investment control over the common shares held by Hardy Capital Ltd., 21 April Fund, Ltd. and 21 April Fund, L.P. participated in the 2023 private placement.

<div align='center'>32

PLAN OF DISTRIBUTION</div>

We are registering the common shares issued to the selling shareholders to permit the resale of these common shares by the holders of the common shares from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling shareholders of the common shares. We will bear all fees and expenses incident to our obligation to register the common shares.

The selling shareholders may sell all or a portion of the common shares beneficially owned by them and offered